The takeover, which had been expected since Lonza confirmed its interest in the capsule firm on Monday , is expected to close in the second quarter of 2017.
Lonza expects to achieve operating synergies of CHF30m a year in three years, citing corporate, procurement and IT infrastructure as areas in which savings will be made.
The Swiss firm also predicted “tax synergies” of CHF15m a year and “efficiency gains.”
Lonza said: "The primary initial focus of this transaction is to ensure a seamless integration while continuing the strong growth trajectory of the Capsugel business.
"Lonza believes that the step-by-step integration will preserve the strong innovation culture and lead to a combined top-line synergy potential of around CHF100m per annum in the mid- to long-term."
A Lonza spokesman told us: "It’s expected that the two Capsugel business units, biopharmaceuticals and consumer health & nutrition, will report into both Lonza segments from closing: Biopharma into Pharma&Biotech, CH&N into Specialty Ingredients."
He also told us that: "We don’t foresee any site closing or divestitures."